Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised tens of millions of renminbi in a pre-Series A financing round led by Lightspeed China, with participation from JinDing Capital and Picus Capital. The funds will support R&D, validation of digital target pipelines, international collaborations, and platform upgrades.
Company Profile
Founded in 2020, Luca Healthcare has developed over 40 digital biomarkers used in clinical trial efficacy evaluations, digital companion products, and standalone digital therapeutics for respiratory, neuromotor, and cognitive diseases. Four products are pending regulatory approval as Class 2 and 3 devices.
Strategic Partnerships
Luca has partnered with Shanghai Pharmaceuticals Holding, AstraZeneca, and Thermo Fisher Scientific to develop digital companion diagnostics and clinical endpoint assessment tools, aiming to integrate digital innovation into drug development and patient care.-Fineline Info & Tech
